Tocagen, Inc.

Industry

  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Technologies
  • Pharmaceuticals

Other Names/Subsidiaries

  • Forte Biosciences, Inc.
See more in Biomedtracker

Latest on Tocagen, Inc.

Scrip

Finance Watch: Joe Jimenez Ventures Into Start-Up World Via Aditum

 
• By Mandy Jackson

Former Novartis AG CEO Joe Jimenez and former Novartis Institutes for BioMedical Research Inc. (NIBR) founding president Mark Fishman have brought their drug development expertise to the start-up

Scrip

Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline

 
• By Joseph Haas and Ian Haydock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker . Menarini To Pay $11.50 Per Share In

Scrip

Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies

 
• By Joseph Haas and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Bicycle Will Perform Early D

Scrip

Reverse Merger With Tocagen Takes Forte’s Dermatology Ambitions Public

 
• By Joseph Haas

Who: Tocagen/Forte Biosciences What: Forte goes public in reverse merger with Tocagen Why: Forte wants access to public financial markets to advance its Phase II live biotherapeutic for atopic de